DK0645145T3 - Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel - Google Patents

Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel

Info

Publication number
DK0645145T3
DK0645145T3 DK94115180.5T DK94115180T DK0645145T3 DK 0645145 T3 DK0645145 T3 DK 0645145T3 DK 94115180 T DK94115180 T DK 94115180T DK 0645145 T3 DK0645145 T3 DK 0645145T3
Authority
DK
Denmark
Prior art keywords
solvent
carboxylate anion
stabilized pharmaceutical
anion content
pharmaceutical preparation
Prior art date
Application number
DK94115180.5T
Other languages
Danish (da)
English (en)
Inventor
Shreerham Narahari Agharkar
Uday S Gogate
Thomas Cavanak
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0645145(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK0645145T3 publication Critical patent/DK0645145T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94115180.5T 1993-09-29 1994-09-27 Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel DK0645145T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (1)

Publication Number Publication Date
DK0645145T3 true DK0645145T3 (da) 1997-04-07

Family

ID=22433231

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94115180.5T DK0645145T3 (da) 1993-09-29 1994-09-27 Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel

Country Status (28)

Country Link
US (1) US5504102A (it)
EP (1) EP0645145B1 (it)
JP (1) JP3447386B2 (it)
KR (1) KR100515631B1 (it)
CN (1) CN1140297C (it)
AT (1) ATE149843T1 (it)
AU (1) AU686651B2 (it)
BE (1) BE1007987A5 (it)
BR (1) BR1100361A (it)
CA (1) CA2132936C (it)
CY (1) CY2035A (it)
CZ (2) CZ287358B6 (it)
DE (1) DE69402022T2 (it)
DK (1) DK0645145T3 (it)
ES (2) ES2098842T3 (it)
FI (1) FI115825B (it)
GR (1) GR3023583T3 (it)
HK (1) HK96797A (it)
HU (1) HU217962B (it)
IL (1) IL111065A (it)
IT (1) IT1279383B1 (it)
NO (1) NO308447B1 (it)
NZ (1) NZ264526A (it)
PL (1) PL176826B1 (it)
RU (1) RU2107500C1 (it)
SG (1) SG50479A1 (it)
TW (1) TW406020B (it)
ZA (1) ZA947482B (it)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674510B1 (en) * 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1209059A (zh) * 1995-12-21 1999-02-24 基因实验室技术有限公司 紫杉烷类组合物及方法
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
CA2347097C (en) * 1998-10-20 2009-06-16 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
WO2001072300A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Uses of metal salts to stabilize taxane-based compositions
WO2001076559A1 (en) 2000-04-10 2001-10-18 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
AU5887201A (en) 2000-05-12 2001-11-20 Samyang Corp Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) * 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
CA2427467C (en) 2000-11-09 2010-01-12 Neopharm, Inc. Sn-38 lipid complexes and methods of use
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
ES2316489T3 (es) 2000-12-05 2009-04-16 Childrens Hospital Los Angeles Composiciones farmaceuticas de fenretinida que tienen biodisponibilidad aumentada y metodos de uso de las mismas.
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2466851C (en) * 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
DK1521572T3 (da) * 2002-07-15 2009-05-04 Alcon Inc Biologisk nedbrydelig film til indförsel af öjenlægemiddel
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
AU2003291458A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
AU2003290647A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
EP1624896B1 (de) * 2003-05-19 2009-07-29 Ebewe Pharma Ges.m.b.H. Nfg. KG Verfahren zur herstellung einer stabilen injizierbaren formulierung von paclitaxel
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
AU2003256786B2 (en) * 2003-07-24 2010-01-07 Fresenius Kabi Oncology Limited Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
DK1694242T3 (da) * 2003-12-17 2014-06-30 Bionumerik Pharmaceuticals Inc Fremgangsmåde til fremstilling af farmaceutiske 7-(2-trimethylsilylethyl)camptothecinpræparater
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
JP2011509299A (ja) 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
SI2254570T1 (sl) * 2008-02-20 2014-03-31 Actelion Pharmaceuticals Ltd. Kombinacija, obsegajoča paklitaksel, za zdravljenje raka na jajčnikih
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
DK2769737T3 (en) 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
EP2637655B1 (en) * 2010-11-08 2019-01-09 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of taxoids
US9198969B2 (en) * 2012-08-15 2015-12-01 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
ES2873600T3 (es) * 2013-02-05 2021-11-03 1Globe Health Inst Llc Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos.
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2016005962A2 (en) 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
EP0674510B1 (en) * 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
NZ258044A (en) * 1992-11-27 1995-12-21 Faulding F H & Co Ltd Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent

Also Published As

Publication number Publication date
BE1007987A5 (fr) 1995-12-05
PL176826B1 (pl) 1999-07-30
CN1107367A (zh) 1995-08-30
ZA947482B (en) 1995-05-15
HK96797A (en) 1997-08-08
PL305240A1 (en) 1995-04-03
NO308447B1 (no) 2000-09-18
RU94037231A (ru) 1996-09-27
FI944448A0 (fi) 1994-09-26
EP0645145A2 (en) 1995-03-29
EP0645145B1 (en) 1997-03-12
NZ264526A (en) 1996-10-28
DE69402022T2 (de) 1997-07-17
NO943583L (no) 1995-03-30
ITRM940621A1 (it) 1996-03-28
KR100515631B1 (ko) 2005-12-08
ITRM940621A0 (it) 1994-09-28
HUT68687A (en) 1995-07-28
BR1100361A (pt) 2000-07-18
AU686651B2 (en) 1998-02-12
IL111065A0 (en) 1994-12-29
ES2095802A1 (es) 1997-02-16
EP0645145A3 (en) 1995-05-24
HU217962B (hu) 2000-05-28
FI944448A (fi) 1995-03-30
SG50479A1 (en) 1998-07-20
RU2107500C1 (ru) 1998-03-27
JP3447386B2 (ja) 2003-09-16
TW406020B (en) 2000-09-21
CN1140297C (zh) 2004-03-03
CZ234994A3 (en) 1995-04-12
CA2132936A1 (en) 1995-03-30
HU9402776D0 (en) 1994-12-28
GR3023583T3 (en) 1997-08-29
CY2035A (en) 1998-02-20
DE69402022D1 (de) 1997-04-17
NO943583D0 (no) 1994-09-27
ES2098842T3 (es) 1997-05-01
US5504102A (en) 1996-04-02
ATE149843T1 (de) 1997-03-15
AU7427394A (en) 1995-04-13
IL111065A (en) 2003-03-12
CA2132936C (en) 1999-06-29
IT1279383B1 (it) 1997-12-10
JPH07179362A (ja) 1995-07-18
CZ287485B6 (cs) 2000-12-13
FI115825B (fi) 2005-07-29
CZ287358B6 (en) 2000-11-15
KR950007872A (ko) 1995-04-15

Similar Documents

Publication Publication Date Title
DK0645145T3 (da) Stabiliseret farmaceutisk præparat og stabiliseringsopløsningsmiddel
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
DE69026555D1 (de) Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität
ATE108329T1 (de) Morphin enthaltende zusammensetzung.
IL90052A (en) :-substituted 4-(quinolin- 2-yl-methoxy) phenylacetic acids and esters, their preparation and pharmaceutical compositions containing them
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
DE69330728D1 (de) Wasserfreie schäumende Zusammensetzung mit geringer Konzentration von Tensiden und hohem Gehalt an Glycerin und Weichmachern, wie Ölen und Estern
NZ218028A (en) Benzimidazole derivatives and pharmaceutical compositions
JPS6416724A (en) Stable and injectable vinca dimer salt solution
ATE79256T1 (de) Zusammensetzung gegen coccidiosis.
KR900014382A (ko) (s)-7-(3-아미노-1-피롤리디닐)-1-시클로프로필-6-플루오로-1,4-디히드로-4-옥소-나프티리딘-3-카르복실산
KR950702561A (ko) 퀴놀린 및 나프티리딘 약물 전구체(quinoline and naphthyridine prodrugs)
EP0345598A3 (de) Zytostatisch wirksame Anthracyclinderivate
JPS6450816A (en) Isosorbide nitrate agent for transcutaneous use
JPS56104813A (en) Composition for rectal infusion containing compound having beta-lactam ring
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
IE780530L (en) Anti-histamine salts and compositions